Literature DB >> 24703714

The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate.

Zhennan She1, Ting Zhang1, Xuling Wang1, Xuan Li1, Yanzhi Song1, Xiaobo Cheng1, Zhenjun Huang1, Yihui Deng2.   

Abstract

Based on the knowledge that sialic acid is a critical element for tumor development and its receptors are highly expressed on the tumor-associated macrophages (TAMs) which play important roles in the growth and metastasis of tumors, we synthesized a sialic acid-octadecylamine conjugate (SA-ODA) and anchored it on the surface of pixantrone (Pix)-loaded liposomes, to achieve an improved anticancer effect. Four Pix formulations (Pix-S, Pix-CL, Pix-PL and Pix-SAL represent solution, conventional liposome, stealth liposome, and SA-ODA modified liposome, respectively) were developed, and various parameters, including drug loading, stability, in vitro release, cytotoxicity and pharmacokinetics, were evaluated. The tumor growth inhibition and toxicity studies were performed in S180-bearing Kunming mice. Pix-S exhibited a strong toxicity to the immune system, accelerated the growth of tumors and reduced the lifespan of mice. In contrast, Pix-SAL displayed the strongest anticancer and life-prolonging effects among all of the formulations in this study. More importantly, injection of Pix-SAL induced a phenomenon whereby the cancerous tissues were "shed" from mice, after which the wound healed. We speculate that this special efficacy may be partly due to the killing of TAMs by Pix-SAL. This study suggests that SA-ODA modified liposomes may serve as an effective intravenous delivery vehicle for Pix.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Liposome pixantrone; Sialic acid–octadecylamine conjugate; Tumor shed; Tumor-associated macrophages

Mesh:

Substances:

Year:  2014        PMID: 24703714     DOI: 10.1016/j.biomaterials.2014.03.022

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency.

Authors:  Ting Zhang; Songlei Zhou; Ling Hu; Bo Peng; Yang Liu; Xiang Luo; Xinrong Liu; Yanzhi Song; Yihui Deng
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

2.  Evaluation of the antitumor effects of vitamin K2 (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate.

Authors:  Jia Shi; Songlei Zhou; Le Kang; Hu Ling; Jiepeng Chen; Lili Duan; Yanzhi Song; Yihui Deng
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

3.  Using hyaluronic acid-functionalized pH stimuli-responsive mesoporous silica nanoparticles for targeted delivery to CD44-overexpressing cancer cells.

Authors:  Zhihui Wang; Yongfeng Tian; Hua Zhang; Yanmei Qin; Dong Li; Li Gan; Fanhong Wu
Journal:  Int J Nanomedicine       Date:  2016-12-05

4.  Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly(sialic acid)-octadecylamine conjugate for lung cancer treatment.

Authors:  Xiang Luo; Ling Hu; Huangliang Zheng; Mingqi Liu; Xinrong Liu; Cong Li; Qiujun Qiu; Zitong Zhao; Xiaobo Cheng; Chaoyang Lai; Yuqing Su; Yihui Deng; Yanzhi Song
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 5.  Nanomaterials for modulating innate immune cells in cancer immunotherapy.

Authors:  Quoc-Viet Le; Geon Yang; Yina Wu; Ho Won Jang; Mohammadreza Shokouhimehr; Yu-Kyoung Oh
Journal:  Asian J Pharm Sci       Date:  2018-08-23       Impact factor: 6.598

6.  Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.

Authors:  Xixi Li; Shunyao Zhu; Ping Yin; Shuangshuang Zhang; Juewen Xu; Qin Zhang; Senlin Shi; Ting Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

7.  Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.

Authors:  Congcong Lin; Xue Zhang; Hubiao Chen; Zhaoxiang Bian; Ge Zhang; Muhammad Kashif Riaz; Deependra Tyagi; Ge Lin; Yanbo Zhang; Jinjin Wang; Aiping Lu; Zhijun Yang
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.